2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-180796
    PKM2 agonist-1 3075162-42-1
    PKM2 agonist-1 (Compound D16) is a highly effective, allosteric PKM2 agonist with an AC50 value of 77 nM. PKM2 agonist-1 inhibits Ang II-induced smooth muscle cell phenotypic switching. PKM2 agonist-1 effectively prevents aortic dissection and results in reduced mortality.
    PKM2 agonist-1
  • HY-180863
    NR1H3 modulator-1 293754-32-2
    NR1H3 modulator-1 is a NR1H3 modulator.
    NR1H3 modulator-1
  • HY-181016
    CX3CR1-IN-2 3105688-14-7 98%
    CX3CR1-IN-2 (Compound 77) is a CX3CR1 inhibitor with an IC50 of 0.04 μM. CX3CR1-IN-2 can block the interaction between CX3CR1 and its ligand fractalkine (CX3CL1). CX3CR1-IN-2 can be used for research of cardiovascular disease, such as heart failure and cardiomyopathy .
    CX3CR1-IN-2
  • HY-18282R
    AZ876 (Standard) 898800-26-5 98%
    AZ876 (Standard) is the analytical standard of AZ876. This product is intended for research and analytical applications. AZ876 is a selective, orally active agonist of liver X receptor (LXRα/β) (Ki=0.007 μM [LXRα, human], 0.011 μM [LXRβ, human]. AZ876 induces the expression of target genes such as ABCA1 and ABCG1, promotes reverse cholesterol transport (RCT) and regulates lipid metabolism and anti-inflammatory effects. AZ876 increases cardiac polyunsaturated fatty acid levels, reduces myocardial fibrosis, and reduces lesion area and monocyte adhesion in atherosclerosis models. AZ876 can be used in cardiovascular disease research, such as preventing and treating β-adrenergic-induced cardiac diastolic dysfunction and inhibiting the progression of atherosclerosis.
    AZ876 (Standard)
  • HY-182960
    KRP-203 monophosphate 749262-82-6
    KRP-203 monophosphate is a monophosphate of KRP-203 (HY-13660). KRP-203 is an orally active sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs.
    KRP-203 monophosphate
  • HY-183030
    Propargyl-DTM 1424958-17-7 98%
    Propargyl-DTM (P39) is an alkyne group molecule that can be used to modify antibodies or antibody fragments. Propargyl-DTM can be used in research on cancer, inflammatory diseases, and cardiovascular diseases.
    Propargyl-DTM
  • HY-18346R
    Mozavaptan (Standard) 137975-06-5 98%
    Mozavaptan (Standard) is the analytical standard of Mozavaptan. This product is intended for research and analytical applications. Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment.
    Mozavaptan (Standard)
  • HY-183649
    BCN-PEG6-OH 2270844-08-9 98%
    BCN-PEG6-OH is a neutralizing agent and anticoagulant inhibitor containing strained alkyne. BCN-PEG6-OH undergoes strain-promoted alkyne-azide cycloaddition (SPAAC) click reaction with azido-Warfarin to generate an inactive product that can be rapidly cleared via the kidneys. In mice, BCN-PEG6-OH effectively reduces the anticoagulant activity of azido-Warfarin in a dose-dependent manner, normalizes prothrombin time, and exhibits no inherent anticoagulant or procoagulant effects when administered alone. BCN-PEG6-OH can be used for the research of drug-induced coagulopathy.
    BCN-PEG6-OH
  • HY-183853
    Arecaidine-propargyl ester 35516-99-5
    Arecaidine-propargyl ester is a selective M2 muscarinic receptor agonist with blood-brain barrier permeability, with a pKi of 5.91 for hm1, 7.06 for hm2, 6.07 for hm3, 6.01 for hm4, and 6.03 for hm5. Arecaidine-propargyl ester stimulates central and peripheral muscarinic receptors. Arecaidine-propargyl ester increases intracellular ROS, induces DNA damage and Apoptosis, and upregulates the expression of MnSOD and SIRT1. Arecaidine-propargyl ester reduces sympathetic nerve outflow, induces dose-dependent hypotension, and triggers negative chronotropic effects at high peripheral doses. Arecaidine-propargyl ester can be used in research related to Alzheimer's disease and glioblastoma.
    Arecaidine-propargyl ester
  • HY-183859
    H142/08 88017-05-4 98%
    H142/08 is a β1-adrenergic receptor-selective agonist. H142/08 induces concentration-dependent relaxation of isolated rat uterus and acts as a chronotropic stimulant to increase atrial rate, and its effects are effectively antagonized by Pafenolol (HY-165495). H142/08 also antagonizes the chronotropic effect of isoproterenol on isolated rat right atrium, but requires a higher proportion of receptor occupancy to produce sufficient stimulatory effects.
    H142/08
  • HY-183907
    Cicletanine 89943-82-8 98%
    Cicletanine is a voltage-dependent Ca2+ channel inhibitor. Cicletanine inhibits α-adrenoceptor-mediated Ca2+ release pathway, and shows vasodilatory effects on isolated vascular smooth muscle. Cicletanine directly stimulates lysosomal and cytoplasmic cholesteryl ester hydrolase activity. Cicletanine can be used for the research of hypertension.
    Cicletanine
  • HY-183921
    SQ 32547 135100-65-1
    SQ 32547 is a dihydropyridine calcium channel inhibitor with antihypertensive and anti-ischemic activities. SQ 32547 modulates sarcolemmal voltage-dependent calcium channels to inhibit calcium influx, and exerts direct anti-ischemic activity by suppressing myocardial contracture formation and reducing lactate dehydrogenase (LDH) release. SQ 32547 can be used in research related to hypertension, angina pectoris and neurogenic inflammation.
    SQ 32547
  • HY-183944
    BN80933 214348-10-4 98%
    BN80933 is a selective neuronal nitric oxide synthase (nNOS) inhibitor with a rat Ki of 0.92 μM. BN80933 inhibits lipid peroxidation, and blocks hypoxia-induced lactate dehydrogenase elevation and delayed 8-epiprostaglandin F2α elevation. BN80933 can be used for the research of stroke, and traumatic brain injury.
    BN80933
  • HY-183954
    MDL-19744A 97233-26-6 98%
    MDL-19744A is an orally active and selective α1-adrenergic receptor antagonist, with rat α1-adrenergic receptor IC50 of 8 nM. MDL-19744A increases renal blood flow, dose-related decreases mean arterial blood pressure, increases urinary sodium excretion, and mediates renal vasodilation. MDL-19744A can be used for the research of hypertension.
    MDL-19744A
  • HY-183978
    KRI-1314 128053-53-2
    KRI-1314 is an orally active human renin inhibitor with selectivity for primate renin over non-primate renin. KRI-1314 competitively inhibits the binding of recombinant human renin to its substrate, reduces plasma renin activity, lowers blood pressure, and exhibits high stability in tissue homogenates. KRI-1314 is applicable to research on renin-dependent hypertension and hypertension-related studies.
    KRI-1314
  • HY-185234
    CTR/AMYR activator-1 3068779-36-9
    CTR/AMYR activator-1 (S configuration of compound 122) is a CTR/AMYR activator. CTR/AMYR activator-1 can be used in the research of bone diseases, metabolic diseases, cardiovascular diseases, and neurodegenerative diseases.
    CTR/AMYR activator-1
  • HY-18681R
    Voxelotor (Standard) 1446321-46-5 98%
    Voxelotor (Standard) is the analytical standard of Voxelotor. This product is intended for research and analytical applications. Voxelotor (GBT 440) is a potent inhibitor of haemoglobin S (HbS) polymerization. Voxelotor has the potential for sickle cell disease (SCD) treatment.
    Voxelotor (Standard)
  • HY-18681S
    Voxelotor-d6 2170187-39-8 98%
    Voxelotor-d6 (GBT 440-d6) is deuterium labeled Voxelotor. Voxelotor (GBT 440) is a potent inhibitor of haemoglobin S (HbS) polymerization. Voxelotor has the potential for sickle cell disease (SCD) treatment.
    Voxelotor-d6
  • HY-18731R
    1400W Dihydrochloride (Standard) 214358-33-5 98%
    1400W (Dihydrochloride) (Standard) is the analytical standard of 1400W (Dihydrochloride). This product is intended for research and analytical applications. 1400W dihydrochloride is the dihydrochloride form of 1400W (HY-18730). 1400W is a slow, tight binding, and highly selective inducible nitric-oxide synthase (iNOS) inhibitor, with a Kd value ≤ 7 nM. 1400W inhibits iNOS induction in microglial cells, and reduces generation of NO, thereby mitigating oxidative stress and neuronal cell apoptosis in the rat cerebral cortex, and improving the spatial memory dysfunction caused by acute hypobaric hypoxia-reoxygenation.
    1400W Dihydrochloride (Standard)
  • HY-18763R
    Indobufen (Standard) 63610-08-2 98%
    Indobufen (Standard) is the analytical standard of Indobufen. This product is intended for research and analytical applications. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes.
    Indobufen (Standard)
Cat. No. Product Name / Synonyms Application Reactivity